Drugs / 68Ga-NOTA-SNA002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05989997 | Nov 2023 → Nov 2024 | cancer | SmartNuclide Biopharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NOTA-SNA002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05989997 ↗ |
| Route | Intravenous | “injected intravenously” NCT05989997 ↗ |